Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028045 | 0.92 | OPRM1 (0.35) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL13721487 | 0.92 | OPRM1 (0.35) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4028041 | 0.92 | OPRM1 (0.35) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4029041 | 0.90 | KDM4E (0.38) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4772539 | 0.90 | OPRM1 (0.34) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4751548 | 0.90 | OPRM1 (0.34) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4751549 | 0.90 | OPRM1 (0.34) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4027446 | 0.88 | OPRM1 (0.35) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4027439 | 0.88 | OPRM1 (0.35) | OPRD1OPRM1KDM2BMEN1KMT2A | |
| SCHEMBL4774673 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | OPRD1 4504/4885OPRM1 4219/4885PKM 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.